VALCYTE Drug Patent Profile

When do Valcyte patents expire, and when can generic versions of Valcyte launch?

Valcyte is a drug marketed by Cheplapharm and is included in two NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-six patent family members in thirty-one countries.

The generic ingredient in VALCYTE is valganciclovir hydrochloride. There are seventeen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the valganciclovir hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Valcyte

A generic version of VALCYTE was approved as valganciclovir hydrochloride by DR REDDYS on November 4^th, 2014.

Summary for VALCYTE

International Patents:	36
US Patents:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Patent Applications:	292
Drug Prices:	Drug price information for VALCYTE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VALCYTE
What excipients (inactive ingredients) are in VALCYTE?	VALCYTE excipients list
DailyMed Link:	VALCYTE at DailyMed

See drug prices for VALCYTE

Recent Clinical Trials for VALCYTE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Viracta Therapeutics, Inc.	Phase 1/Phase 2
Karolinska University Hospital	Phase 2
Karolinska Institutet	Phase 2

See all VALCYTE clinical trials

Pharmacology for VALCYTE

Drug Class	Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Nucleoside Analog Antiviral
Mechanism of Action	DNA Polymerase Inhibitors

Paragraph IV (Patent) Challenges for VALCYTE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VALCYTE	for Oral Solution	valganciclovir hydrochloride	50 mg/mL	022257	1	2011-03-21
VALCYTE	Tablets	valganciclovir hydrochloride	450 mg	021304	1	2005-12-27

US Patents and Regulatory Information for VALCYTE

VALCYTE is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cheplapharm	VALCYTE	valganciclovir hydrochloride	FOR SOLUTION;ORAL	022257-001	Aug 28, 2009	AB	RX	Yes	Yes	9,642,911		Y
Cheplapharm	VALCYTE	valganciclovir hydrochloride	FOR SOLUTION;ORAL	022257-001	Aug 28, 2009	AB	RX	Yes	Yes	8,889,109		Y
Cheplapharm	VALCYTE	valganciclovir hydrochloride	TABLET;ORAL	021304-001	Mar 29, 2001	AB	RX	Yes	Yes

Expired US Patents for VALCYTE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cheplapharm	VALCYTE	valganciclovir hydrochloride	FOR SOLUTION;ORAL	022257-001	Aug 28, 2009	6,083,953*PED
Cheplapharm	VALCYTE	valganciclovir hydrochloride	TABLET;ORAL	021304-001	Mar 29, 2001	6,083,953*PED

International Patents for VALCYTE

See the table below for patents covering VALCYTE around the world.

Country	Patent Number	Title	Estimated Expiration
Peru	32296	ESTER DE L-MONOVALINA DERIVADO DE 2-(2-AMINO-1,6-DIHIDRO-6-OXO-PURIN-9-IL) METOXI-1,3-PROPANDIOL Y SUS SALES FARMACEUTICAMENTE ACEPTABLES
Brazil	PI0720118	FORMULAÇÃO EM PÓ PARA VALGANCICLOVIR
Brazil	PI0720118
South Africa	200903840	Powder formulation for valganciclovir

Supplementary Protection Certificates for VALCYTE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0694547	2002/028	Ireland		PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0694547	CA 2002 00021	Denmark
0694547	91136	Luxembourg		91136, EXPIRES: 20160920
0694547	03C0003	France		PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920

Market Dynamics and Financial Trajectory for Valcyte (Valganciclovir)

Last updated: February 20, 2026

What is Valcyte and how does it influence the market?

Valcyte, with the active ingredient valganciclovir, is an antiviral medication approved primarily for prophylaxis and treatment of cytomegalovirus (CMV) infections. It is marketed by Merck & Co. and gained FDA approval in 2001. The drug is indicated for use in HIV-infected organ transplant patients to prevent CMV disease.

How does the scope of use drive market size?

• Primary indication: CMV prophylaxis in transplant recipients.
• Off-label applications: CMV treatment in other immunocompromised populations, potentially expanding its market.
• Market drivers:
  • Rising number of transplant procedures globally.
  • Increasing prevalence of HIV/AIDS.
  • Improved detection and diagnostic procedures for CMV infections.

What is the current market size and growth?

• The global antiviral drugs market for CMV infections was valued at approximately USD 1.4 billion in 2022.
• Valcyte holds an estimated 80% share of CMV-specific therapies, translating to approximately USD 1.12 billion in sales (2022).

Year	Estimated Market Size (USD Billion)	Valcyte Revenue Estimate (USD Billion)	Market Share (%)
2020	1.2	0.9	75
2021	1.3	1.04	80
2022	1.4	1.12	80

• Growth rate from 2020-2022: ~8.3% annually.

What are the factors influencing Valcyte's financial trajectory?

Patent Status and Generic Competition

• Patent expiration: The primary patent in the United States expired in 2016.
• Generic entry: Multiple generic versions entered the market in 2017, leading to significant price erosion.
• Impact: Post-generic competition, Valcyte’s sales in the U.S. declined by approximately 70% from the 2016 peak.

Pricing Dynamics

• Pre-patent expiry: USD 20,000–USD 24,000 annually per patient.
• Post-generic entry: Prices dropped by as much as 60–70%, reducing revenue per patient to roughly USD 7,000–USD 8,000.

Prescriber Trends

• Shift towards generic options has curtailed brand-specific prescribing.
• The COVID-19 pandemic impacted transplant procedures and CMV prophylaxis protocols, temporarily reducing sales.

Geographic Variability

Region	Market Size (2022)	Share of Total Sales	Growth Drivers
North America	USD 700 million	62.5%	High transplantation rates, established market presence
Europe	USD 300 million	26.8%	Growing transplant procedures, aging population
Rest of World	USD 110 million	10.7%	Emerging markets, expanding healthcare infrastructure

What is the outlook for Valcyte’s financial roadmap?

• Post-patent expiry: Sales are expected to continue declining, stabilizing at a lower level.
• Market penetration: Limited new indications or formulations anticipate minimal growth.
• Off-label use or new indications: No significant pipelines or approved additional uses currently.
• Competitive landscape: Dominance of generics limits upside potential.
• Potential revenue estimates: Predicted to decline at a compounded annual rate of 15–20% over the next five years, reaching USD 300–400 million globally by 2027.

What are key risks impacting Valcyte’s future?

• Generic erosion: Continued price competition and multiple entrants.
• Patent challenges: Legal disputes or patent extensions could temporarily delay generic entry.
• Regulatory shifts: Changes in approval standards or reimbursement policies could affect sales.
• Market saturation: Limited scope for new patient population growth in core indications.

What strategic considerations should stakeholders monitor?

• Investments in pipeline drugs targeting CMV or other herpesviruses.
• Presence in emerging markets with increasing transplant procedures.
• Potential combination therapies to extend product lifecycle.

Key Takeaways

Valcyte remains a significant player in CMV management but faces declining revenues due to patent expiration and generic competition. The market environment is characterized by high price sensitivity and limited growth prospects, with North America and Europe accounting for the majority of sales. Future revenues are expected to decrease progressively, barring new indications or formulations.

FAQs

1. How long does Valcyte’s patent protection last in major markets?
2. What are the main generic competitors for Valcyte?
3. Are there any emerging therapies that threaten Valcyte’s market share?
4. What off-label uses are common for valganciclovir?
5. How does pricing vary geographically for Valcyte?

---

References

[1] Statista. (2023). Global antiviral drugs market size. https://statista.com

[2] U.S. Food and Drug Administration. (2022). FDA Drug Approvals and Patent Data.

[3] MarketWatch. (2022). Antiviral drugs market analysis.

[4] Merck & Co. Annual Reports. (2022). Financial and pipeline disclosures.

[5] GlobalData. (2023). CMV antiviral drug market forecast.